Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Stock Information for Carisma Therapeutics Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Carisma Therapeutics Inc Com

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote "FOR" All Proposals at March 2 Special Meeting
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TIG, SESN, CINC, AJRD
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.